D.E. Shaw & Co
GLUE icon

D.E. Shaw & Co’s Monte Rosa Therapeutics GLUE Stock Holding History

D.E. Shaw & Co’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Sell
66,327
-19,161
-22% -$366K ﹤0.01% 3382
2025
Q4 		$1.34M Buy
85,488
+35,275
+70% +$475K ﹤0.01% 3349
2025
Q3 		$372K Buy
+50,213
New +$266K ﹤0.01% 4010
2025
Q1 		– Sell
-70,114
Closed -$487K – 4432
2024
Q4 		$487K Buy
70,114
+51,823
+283% +$389K ﹤0.01% 3635
2024
Q3 		$96.9K Sell
18,291
-5,131
-22% -$25.9K ﹤0.01% 4252
2024
Q2 		$87.6K Buy
+23,422
New +$119K ﹤0.01% 4181
2022
Q1 		– Sell
-24,085
Closed -$492K – 5676
2021
Q4 		$492K Sell
24,085
-23,039
-49% -$482K ﹤0.01% 4410
2021
Q3 		$1.05M Buy
+47,124
New +$1.35M ﹤0.01% 3565

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

D.E. Shaw & Co's GLUE Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Monte Rosa Therapeutics (GLUE) stake by 22% in Q1 2026, selling an estimated $366K and leaving 66,327 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3382.

D.E. Shaw & Co first reported a position in GLUE in Q3 2021 and has held it in 8 quarters since. The position peaked at $1.34M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • D.E. Shaw & Co held 66,327 shares of Monte Rosa Therapeutics worth $1.09M as of Q1 2026.
  • D.E. Shaw & Co sold 19,161 Monte Rosa Therapeutics shares in Q1 2026, an estimated $366K.
  • Monte Rosa Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3382 holding.
  • D.E. Shaw & Co first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • D.E. Shaw & Co's Monte Rosa Therapeutics position peaked at $1.34M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.